Navigation Links
Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences
Date:6/2/2009

PRINCETON, N.J., June 2 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces management will present at the Goldman Sachs Global Healthcare Conference and the Needham Healthcare Conference. Both conferences will be held in New York, NY.

Schaefer Price, Pharmasset's President and Chief Executive Officer, will provide an overview of the company at the Goldman Sachs Global Healthcare Conference on Tuesday, June 9, 2009 at 3:10 PM (ET) and at the Needham Conference on Thursday June 11, 2009 at 1:00 PM (ET).

To access a simultaneous webcast of Mr. Price's overview via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm. Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast.

A replay of the webcast will be available on Pharmasset's website for thirty days following the conference. The investor presentation will be available for download in PDF format immediately following the presentation in the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on the development of Racivir(R) for the treatment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleos(t)ide analogs, a class of compounds which act to inhibit the enzymes required for viral replication. We currently have three clinical-stage product candidates: R7128, a nucleoside analog for chronic HCV infections, has initiated a Phase 2b clinical trial in combination with Pegasys plus Copegus through a strategic collaboration with Roche; PSI-7851, an unpartnered, next generation HCV nucleotide analog, which recently began Phase 1 clinical studies and Racivir, for the treatment of HIV that has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2008 and our Quarterly Report on Form 10-Q for the period ended March 31, 2009 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.

    Contact
    Richard E. T. Smith, Ph.D.
    VP, Investor Relations and Corporate Communications
    richard.smith@pharmasset.com
    Office: +1 (609) 613-4181


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
2. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
3. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
4. Pharmasset Reports Fiscal Year End 2008 Financial Results
5. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
6. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
7. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
8. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
9. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
10. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2017)... 2017  Researchers from DRUGSCAN ® and INC ... a live, complimentary webinar titled, "Untangling methods to tamper ... real world" on Wednesday June 28, 2017 from 12:00 ... webinar will feature interviews with recreational and dependent prescription ... techniques abusers use to prepare opioid tablets for routes ...
(Date:6/14/2017)... , June 14, 2017 The Bio ... City of Fremont and the ... the bio-pharma industry in California ... enabling executive networking, and fostering workforce development. The primary ... and growth of start-ups, as well as small and ...
(Date:6/11/2017)... , June 10, 2017  Eli Lilly and Company ... from three Phase 3 studies of galcanezumab, an investigational ... including late-breaking data on several key secondary endpoints for ... results from these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will ... annual scientific meeting in Boston . ...
Breaking Medicine Technology:
(Date:6/27/2017)... ... ... Harbour , a DAO (decentralized autonomous organization) that harnesses the wisdom of ... technical specifications . , 2017 has seen an explosion of token launches by blockchain ... will garner the greatest ROI. Dean Eigenmann, Co-founder and CEO of Harbour, said, “We ...
(Date:6/27/2017)... ... June 27, 2017 , ... From June 20-22, EarQ and Widex ... Syracuse, New York, where EarQ is headquartered. , Together, the organizations educate hearing ... today’s savvy consumer, and the latest in hearing technology. At the event, EarQ ...
(Date:6/27/2017)... ... June 27, 2017 , ... PR ... an upcoming case studies guidebook. This guidebook offers an excellent branding and exposure ... include articles, case studies and how-to’s that fall into the following categories:, ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... Hammer Strength, ... Association (NBSCA) have named Javair Gillett of the Houston Rockets the NBSCA Strength & ... the award is decided by NBSCA members who vote to select the coach who ...
(Date:6/27/2017)... ... June 27, 2017 , ... Children’s National Health System ... rankings, with its Neonatology program ranking #1 out of more than 1500 neonatal ... to the coveted Honor Roll, a distinction given to the top performing children’s hospitals ...
Breaking Medicine News(10 mins):